Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1200 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older)	I-131-Apamistamab (Iomab-B)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2017	View \| Download
Ipatasertib in addition to paclitaxel for locally advanced or metastatic triple-negative breast cancer	Ipatasertib (GDC-0068; RG7440) , Paclitaxel (Taxol; paclitaxel albumin)	Breast cancer	Breast Cancer	2020	View \| Download
Ipatasertib in combination with abiraterone and prednisone for metastatic castrate resistant prostate cancer – first line	Abiraterone acetate (Zytiga; Yonsa) , Ipatasertib (GDC-0068; RG7440) , Prednisone (Decadron; Lodotra)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Iptacopan for paroxysmal nocturnal haemoglobinuria	Iptacopan	Paroxysmal nocturnal haemoglobinuria (PNH)	Haematology	2022	View \| Download
Iptacopan for treating complement 3 glomerulopathy	Iptacopan	Complement 3 glomerulopathy	Immunology , Neurology	2023	View \| Download
Irinotecan liposome injection with oxaliplatin, 5-fluorouracil and leucovorin for previously untreated metastatic pancreatic cancer	5-Fluorouracil , Irinotecan liposome injection , Leucovorin , Oxaliplatin	Pancreatic cancer	Gastrointestinal Cancer	2024	View \| Download
Isatuximab in addition to bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma – first line	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2021	View \| Download
Isatuximab in addition to carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma	Carfilzomib (Kyprolis; ONO-7057) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Isatuximab in Addition to Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Isatuximab induction therapy with bortezomib, lenalidomide and dexamethasone for previously untreated multiple myeloma	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2023	View \| Download